Advanced Enzyme Technologies Limited — Investor Meet, 19-11-2024: Analysts/Institutional Investor Meet/Con. Call Updates

**Financial Performance:** Advanced Enzyme Technologies reported Q2 revenues of ₹1,461 million, reflecting a 7% decline year-over-year and a 5% drop sequentially. EBITDA decreased by 17% to ₹424 million, with margins falling to 29%. Profit after tax (PAT) was ₹334 million, a reduction of 5% year-on-year. The decrease in revenues was attributed to higher sales reversals of ₹83 million due to stricter revenue recognition criteria. The company anticipates recovery in the second half of the year, driven by deferred revenue recognition from Q2.

**Future Outlook and Growth Drivers:** Management expressed confidence in outperforming the first half's results, emphasizing that the US market remains a strength with a year-to-date sales increase of 24%. Despite current challenges, including fierce competition in the Human Nutrition segment and extended lead times in the supply chain, they expect a shift in performance in Q3.

**Order Book and Operational Updates:** The company is focusing on enhancing its R&D, introducing new biocatalyst solutions, and building an independent testing facility to streamline operations for their clients. The Human Nutrition segment, which comprises 68% of revenue, saw a 6% year-on-year decline largely due to lower demand in the pharma API market.

**Analyst Q&A Insights:** Analysts questioned revenue projections and profitability dynamics. Management clarified that sales reversals had adversely impacted metrics and noted slight recovery signals in deferred sales from the quarter. There were also follow-up questions regarding competition in the serratiopeptidase market and the delayed sales in the biocatalysts segment.

**Market or Regulatory Updates:** Regulatory hurdles, particularly in freight logistics, posed challenges for shipping, impacting sales in international markets. Management noted no significant customer losses; however, they recognized that higher freight costs affected overall profitability.

**Strategic Focus Areas:** The management stressed a strategic pivot towards accelerating R&D efforts and product development to enhance market competitiveness, aiming to increase R&D capacity threefold.

**Investor Insight:** Given the ongoing operational challenges juxtaposed with potential recovery signals and management's commitment to strengthening R&D, the observed financial health and growth outlook could favor maintaining current positions. This infrastructure investment alongside anticipated market recovery suggests a cautiously optimistic stance.